Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
Public ClinicalTrials.gov record NCT04572893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities.
Study identification
- NCT ID
- NCT04572893
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2020 (Actual)
- Primary completion
- Feb 22, 2024 (Actual)
- Completion
- Feb 22, 2024 (Actual)
- Last update posted
- May 21, 2025
2020 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0007 | La Jolla | California | 92037 | — |
| Local Institution - 0010 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0009 | Tampa | Florida | 33612 | — |
| Local Institution - 0002 | Chicago | Illinois | 60611-5966 | — |
| Local Institution - 0003 | Boston | Massachusetts | 02115 | — |
| Local Institution - 0005 | Rochester | Minnesota | 55905 | — |
| Local Institution - 0006 | Cleveland | Ohio | 44195-0001 | — |
| Local Institution - 0019 | Columbus | Ohio | 43210 | — |
| Local Institution - 0001 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0004 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0008 | Germantown | Tennessee | 38138 | — |
| Local Institution - 0018 | Austin | Texas | 78705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04572893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2025 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04572893 live on ClinicalTrials.gov.